Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivir

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.
Market Dynamics
Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.
However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.
Key features of the study:
This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 – 2027, considering 2018 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Hepatitis Drugs Market, By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
Global Hepatitis Drugs Market, By Disease Type:
Hepatitis B
Hepatitis C
Others
Global Hepatitis Drugs Market, By Route of Administration:
Oral
Injection
Global Hepatitis Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatitis Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Interferon Alphas
HIV NRTIs
Hepatitis B NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Merck & Co. Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Gilead Sciences Inc.
AbbVie Inc.
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
LAURUS Labs
Zydus Cadila
Hetero Healthcare Limited
GlaxoSmithKline PLC
Cipla Inc.
“*” marked represents similar segmentation in other categories in the respective section


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Disease Type
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Epidemiology Analysis
Reimbursement Scenario
PEST Analysis
4. Global Hepatitis Drugs Market, By Drug Class, 2019 – 2027 (US$ Million)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
Interferon Alphas
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
HIV NRTIs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Nucleotide Polymerase / NS5A Inhibitor Combinations
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Hepatitis C Protease / NS5A Inhibitor Combinations
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
NS5A Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Nucleotide Polymerase Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Nucleoside Analogue Antivirals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Thrombopoiesis Stimulating Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
5. Global Hepatitis Drugs Market, By Disease Type, 2019 – 2027, (US$ Million)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
Hepatitis B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Hepatitis C
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
6. Global Hepatitis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
7. Global Hepatitis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017 – 2027
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
8. Global Hepatitis Drugs Market, By Region, 2019 – 2027, (US$ Million)
Introduction
Market Share Analysis, By Region, 2019 and 2027 (%)
Y-o-Y Growth Analysis, By Region, 2017 – 2027
Regional Trends
North America
Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
North Africa
Central Africa
South Africa
Middle East
Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)l
Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
GCC Countries
Israel
Rest of Middle East
9. Competitive Landscape
Company Profiles
Merck & Co. Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Gilead Sciences Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AbbVie Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bristol Myers Squibb Company
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
F. Hoffmann-La Roche Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
LAURUS Labs
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Zydus Cadila
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Hetero Healthcare Limited
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlaxoSmithKline PLC.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Cipla Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Analyst Views
10. Section
References
Research Methodology
About Us and Sales Contact
*Browse 35 market data tables and 27 figures on Global Hepatitis Drugs Market” - Global forecast to 2026”

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook